{"slug":"tesamorelin-neuropathy","verification":{"valid":true,"entries":2,"head":"c254bcb023a5c4bdc278d81300dd2804a8ca78880088ef1dfb608b13732d6cb6"},"energy":{"passes":2,"tokens_in":16147,"tokens_out":2701,"tokens_total":18848,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"c254bcb023a5c4bdc278d81300dd2804a8ca78880088ef1dfb608b13732d6cb6"},"provenance":[{"ts":"2026-06-29T23:18:00.670Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Neuropathy\nSlug: tesamorelin-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptid","response":"{\n  \"slug\": \"tesamorelin-neuropathy\",\n  \"title\": \"Tesamorelin for Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Inflammation can persist. Over time, motor and sensory function decline because repair pathways lag behind ongoing breakdown.\\n\\n## Why Tesamorelin might help you\\n\\nTesamorelin stimulates the growth hormone axis. It raises GH and IGF-1 levels. If your neuropathy involves impaired axonal regeneration or muscle atrophy after nerve injury, this pathway is discussed for potential tissue repair support.\\n\\n1. Therefore for you: If axonal regrowth is a limiting factor, Tesamorelin is studied because GH/IGF-1 signaling has been linked in animal models to faster nerve fiber extension.\\n2. Therefore for you: If muscle wasting follows denervation, the same axis may help preserve or rebuild muscle tissue indirectly.\\n3. Therefore for you: If visceral fat or metabolic stress adds to nerve load, Tesamorelin's documented effect on reducing abdominal fat could ease secondary strain, though this remains separate from direct nerve effects.\\n4. Therefore for you: Tesamorelin targets repair signaling rather than symptom masking.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tesamorelin addresses the GH axis and visceral fat layer. No sibling peptides are in scope here.\\n\\n## What the evidence actually shows\\n\\nHuman data: One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) is testing tesamorelin after peripheral nerve injury repair. The trial enrolls patients with ulnar nerve lacerations. It measures motor and sensory recovery over one year. As of 2026 the study remains active with no published efficacy results.\\n\\nPreclinical data: Animal studies indicate growth hormone improves nerve regener","tokens_in":16147,"tokens_out":2701,"cost":0,"prev":"genesis","hash":"680aa8d693837e73ea0cae398b12c10016159a4c3a64a7ee29dbeeaf117e9eec"},{"ts":"2026-07-17T02:42:24.485Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-neuropathy","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"680aa8d693837e73ea0cae398b12c10016159a4c3a64a7ee29dbeeaf117e9eec","hash":"c254bcb023a5c4bdc278d81300dd2804a8ca78880088ef1dfb608b13732d6cb6"}]}